# Lipoprotein-associated phospholipase A2 (Lp-PLA2): a key hub linking lipid metabolism and immune inflammation

**Authors:** Dandan Li, Yuanbo Qian, Li Wan, Kaixin Zhang, Lifeng Song, Xianjing Zhang, Xiaorong Yang

PMC · DOI: 10.3389/fimmu.2026.1705738 · Frontiers in Immunology · 2026-01-26

## TL;DR

Lp-PLA2 is an enzyme linking lipid metabolism and immune inflammation, with roles in diseases like atherosclerosis and cancer.

## Contribution

This review synthesizes Lp-PLA2's mechanisms, disease associations, and therapeutic potential as a biomarker and target.

## Key findings

- Lp-PLA2 hydrolyzes PAF to produce anti-inflammatory LysoPAF and oxLDL to generate pro-inflammatory LysoPC and oxFA.
- It is implicated in atherosclerosis, diabetes, Alzheimer’s disease, cancer, and autoimmune disorders.
- Pharmacological targeting of Lp-PLA2 has shown inconsistent clinical outcomes due to its complex roles.

## Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as phospholipase A2 group VII (PLA2G7), is an enzyme that serves as a critical nexus between lipid metabolism and immune regulation. It exhibits dual and context-dependent functions by hydrolyzing platelet-activating factor (PAF) and oxidized low-density lipoprotein (oxLDL). The degradation of PAF results in the production of Lysoplatelet activating factor (LysoPAF), which attenuates inflammatory signaling. In contrast, the hydrolysis of oxLDL generates lysophosphatidylcholine (LysoPC) and oxidized fatty acids (oxFA), which exacerbate vascular inflammation, promote macrophage M1 polarization, and inhibit CD8+ T cell activity. Through these pathways, Lp-PLA2 is implicated in a range of diseases, including atherosclerosis, diabetes, Alzheimer’s disease, cancer, autoimmune disorders, and inflammation associated with infections. Despite extensive pharmacological interventions targeting this enzyme, clinical outcomes have been inconsistent, reflecting its complex roles across various pathophysiological contexts. This review synthesizes current knowledge on the mechanisms of Lp-PLA2, its associations with diseases, and its therapeutic implications, emphasizing its potential as both a biomarker and a therapeutic target at the intersection of lipid metabolism and immune response.

## Linked entities

- **Genes:** PLA2G7 (phospholipase A2 group VII) [NCBI Gene 7941]
- **Proteins:** PLA2G7 (phospholipase A2 group VII)
- **Diseases:** atherosclerosis (MONDO:0005311), diabetes (MONDO:0005015), Alzheimer’s disease (MONDO:0004975), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, PLA2G7 (phospholipase A2 group VII) [NCBI Gene 7941] {aka LDL-PLA2, LP-PLA2, PAFAD, PAFAH}
- **Diseases:** inflammation (MESH:D007249), diabetes (MESH:D003920), Alzheimer's disease (MESH:D000544), atherosclerosis (MESH:D050197), cancer (MESH:D009369), autoimmune disorders (MESH:D001327), infections (MESH:D007239)
- **Chemicals:** PAF (MESH:D010972), oxFA (-), LysoPC (MESH:D008244), lipid (MESH:D008055)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12883742/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12883742/full.md

## References

129 references — full list in the complete paper: https://tomesphere.com/paper/PMC12883742/full.md

---
Source: https://tomesphere.com/paper/PMC12883742